Regulatory authorities review use of galantamine in mild cognitive impairmentBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7486.276-b (Published 03 February 2005) Cite this as: BMJ 2005;330:276
- Susan Mayor
Regulatory authorities are reviewing data suggesting that galantamine (Reminyl), a cholinesterase inhibitor licensed for mild to moderate dementia in Alzheimer's disease, was associated with increased mortality among patients with mild cognitive impairment.
The manufacturer, Johnson & Johnson Pharmaceutical Research & Development, made the announcement last week, following two trials that it conducted. The studies combined included 2048 people aged 50 years and over with mild cognitive impairment (insufficient impairment to be diagnosed as dementia). The participants were randomly assigned to receive 8 mg or 12 mg twice …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial